Momenta Pharmaceuticals Reaches Analyst Target Price
June 20, 2017 at 09:18 AM EDT
In recent trading, shares of Momenta Pharmaceuticals Inc (MNTA) have crossed above the average analyst 12-month target price of $17.00, changing hands for $17.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..